for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Charles River Laboratories Intl. Inc

CRL.N

Latest Trade

211.99USD

Change

-7.62(-3.47%)

Volume

9,213

Today's Range

210.80

 - 

214.44

52 Week Range

95.79

 - 

228.69

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
219.61
Open
214.44
Volume
9,213
3M AVG Volume
7.43
Today's High
214.44
Today's Low
210.80
52 Week High
228.69
52 Week Low
95.79
Shares Out (MIL)
49.68
Market Cap (MIL)
10,909.92
Forward P/E
30.27
Dividend (Yield %)
--

Next Event

Q3 2020 Charles River Laboratories International Inc Earnings Release

Latest Developments

More

Charles River Laboratories Announces Q2 Revenue Of $682.6 Mln

Charles River Laboratories Announces First-Quarter 2020 Results

Charles River Labs Reports Q4 Non-GAAP Earnings Per Share $2.01

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Charles River Laboratories Intl. Inc

Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company's clients' manufacturing activities.

Industry

Biotechnology & Drugs

Contact Info

251 Ballardvale St

WILMINGTON, MA

01887-1096

United States

+1.781.2226000

https://www.criver.com/

Executive Leadership

James C. Foster

Chairman of the Board, President, Chief Executive Officer

David Ross Smith

Chief Financial Officer, Corporate Executive Vice President

William D. Barbo

Corporate Executive Vice President and Chief Commercial Officer

Birgit Girshick

Corporate Executive Vice President, Global Discovery and Safety Assessment, Biologics and Avian

Joseph W. LaPlume

Corporate Executive Vice President, Corporate Development and Strategy

Key Stats

1.72 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

1.9K

2018

2.3K

2019

2.6K

2020(E)

2.9K
EPS (USD)

2017

5.270

2018

6.030

2019

6.730

2020(E)

7.260
Price To Earnings (TTM)
40.42
Price To Sales (TTM)
3.97
Price To Book (MRQ)
6.22
Price To Cash Flow (TTM)
22.24
Total Debt To Equity (MRQ)
129.00
LT Debt To Equity (MRQ)
125.93
Return on Investment (TTM)
6.45
Return on Equity (TTM)
5.53

Latest News

Latest News

BRIEF-Charles River Laboratories Increases Size Of Board To 12

Charles River Laboratories International Inc:

Blue-blooded crabs at heart of pharma dispute on drug testing

If you've received a vaccination, hip replacement or chemotherapy without suffering toxic shock, chances are you've benefited from a vast bloodletting of horseshoe crabs.

BRIEF-Charles River Laboratories Q4 GAAP Loss Per Share $0.63

Charles River Laboratories International Inc:

BRIEF-Charles River Laboratories reports Q3 non-GAAP EPS of $1.30

Charles River Laboratories International Inc:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up